Access to the latest treatment innovations is a human right.
We cannot afford to stop until our treatments are available to everyone who needs them. To date, new, six-month treatments for DR-TB have been procured to reach.
100,000
patients
Signature Market Access Initiatives
PeerLINC Knowledge Hub
The PeerLINC Knowledge Hub follows a peer-to-peer model. It connects experts in countries who have rapidly adopted new TB treatments with other countries interested in adopting, so they can share…
Fast Track the Cure
Fast Track the Cure brings communities around the world together to raise awareness and facilitate access to new treatments for drug-resistant TB, while ramping up advocacy to tell world leaders…
LIFT-TB
 The LIFT-TB initiative seeks to save the lives and livelihoods of people with tuberculosis (TB), their families, and their communities by broadening and accelerating the adoption and scale up of…
SLASH-TB
Generate a customized cost effectiveness analysis for implementing six-month drug-resistant TB treatments The Model Various studies show that when used to treat drug-resistant TB (DR-TB) the BPaL regimen has the…
Featured Research
Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis
Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis
Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients
Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients
Update on Pretomanid, in Combination with Bedaquiline and Linezolid (the BPaL Regimen) in Drug-Resistant TB
Update on Pretomanid, in Combination with Bedaquiline and Linezolid (the BPaL Regimen) in Drug-Resistant TB
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines
TB Market Research
Determining the Pediatric TB Burden
A major historical challenge in tackling childhood TB has been understanding the scope of the…
The Global TB Market
Pathway to Patients: Charting the Dynamics of the Global TB Drug Market, was the first…
Value Propositions of New Regimens
TB Alliance sought opinions on attributes that key decision-makers want in new regimens, including safety,…
Understanding Regimen Change
TB Alliance investigated health systems to understand the regimen change process, in order to accelerate…
Defining the Role of the Private Sector in Treatment
TB treatment is widely understood to be a public sector responsibility. However, our research found…